RESUMEN
BACKGROUND: New urinary biomarkers like neutrophil gelatinase-associated lipocalin (NGAL), liver-type fatty acid binding protein (L-FABP), and kidney injury molecule-1 (KIM-1) open the opportunity to detect kidney injuries in early stages. Our study aimed at evaluating NGAL, L-FABP, and KIM-1 in comparison to established markers of urine protein differentiation for detection of renal dysfunction. METHODS: On the basis of the PROTIS expert system (for differentiation of glomerulo-/tubulopathy) urine and plasma samples of 263 randomly selected patients were routinely examined (urine: total protein, albumin, IgG, α1-microglobulin, creatinine, and dip stick results for leukocytes, blood, protein, glucose, pH, and nitrite; plasma: creatinine and cystatin C) followed by the analysis of the new urine biomarkers NGAL (CMIA), L-FABP (ECLIA), and KIM-1 (ELISA). RESULTS: Of the three new markers L-FABP showed the highest correlation with α1-microglobulin (r=0.76, p<0.01) and was closest associated with the degree of tubular proteinuria assessed by the PROTIS system. NGAL distinguished the PROTIS proteinuria groups with distinctive tubular proteinurias from the controls as well, but revealed a marked diagnostic influence by leukocyturia. Urinary KIM-1 revealed only a weak diagnostic value for the detection of renal injury. CONCLUSIONS: Urinary NGAL and L-FABP proved to be promising candidates for detecting injuries of the renal tubular system over a broad range of clinical conditions. L-FABP showed a better diagnostic performance and a lower interference by leukocyturia and hematuria than NGAL. Both markers may serve as sensitive tissue injury markers in addition to the established markers of renal functional impairment.
Asunto(s)
Proteínas de Fase Aguda/orina , Proteínas de Unión a Ácidos Grasos/orina , Enfermedades Renales/fisiopatología , Enfermedades Renales/orina , Lipocalinas/orina , Glicoproteínas de Membrana/orina , Proteínas Proto-Oncogénicas/orina , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Biomarcadores/orina , Niño , Preescolar , Enfermedad Crónica , Proteínas de Unión a Ácidos Grasos/sangre , Femenino , Hematuria/sangre , Hematuria/complicaciones , Hematuria/orina , Receptor Celular 1 del Virus de la Hepatitis A , Humanos , Riñón/lesiones , Riñón/metabolismo , Enfermedades Renales/sangre , Enfermedades Renales/diagnóstico , Lipocalina 2 , Lipocalinas/sangre , Masculino , Glicoproteínas de Membrana/sangre , Persona de Mediana Edad , Proteinuria/sangre , Proteinuria/diagnóstico , Proteinuria/orina , Proteínas Proto-Oncogénicas/sangre , Receptores Virales/sangre , Adulto JovenRESUMEN
OBJECTIVE: The goal with this study was to evaluate the analytical performance of a new cystatin C immunoassay (Tina-quant a Cystatin C, Roche Diagnostics GmbH). The evaluation was carried out at four centers according to a standardized protocol. MATERIAL AND METHODS: The Tina-quant a Cystatin C is a latex particle-enhanced immunoturbidimetric assay. Roche cobas 6000, MODULAR ANALYTICS SWA and COBAS INTEGRA instruments were included in the study. Method comparison studies were carried out against two turbidimetric methods (Dako Cystatin C, Gentian Cystatin C), and one nephelometric method (Siemens N-Latex Cystatin C). RESULTS: Linearity was proven throughout the measuring range from 0.4 to 8 mg/L. Within-run CVs ranged from 0.7-2.8%, and total CVs from 1.4-4.7 % (concentration range 0.6-3.9 mg/L). Comparable results were obtained with paired serum and Li-heparinate plasma samples. Good agreement was achieved in the comparisons between the Tina-quant a Cystatin C assay and the other commercially available cystatin C assays, two different turbidimetric methods (slope range 0.88-1.04, intercept < 0.17 mg/L, r > or = 0.993) and one nephelometric assay (slope range 0.90-1.05, intercept < 0.21 mg/L, r > or = 0.986). CONCLUSIONS: The Tina-quant a Cystatin C assay was shown to be precise and accurate with proven linearity over the measuring range. Good comparability was obtained with other commercially available assays for the determination of cystatin C. The Tina-quant a Cystatin C assay is very well suited for clinical use on routine clinical chemistry analysers to detect renal dysfunction with a 24 h availability.